The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status

Neuro-Oncology

Volumn 15, Issue 9, 2013, Pages 1200-1211

  Johansson, Mikael ^a,b   Oudin, Anaïs ^a   Tiemann, Katja ^a   Bernard, Amandine ^a   Golebiewska, Anna ^a   Keunen, Olivier ^a   Fack, Fred ^a   Stieber, Daniel ^a   Wang, Baofeng ^b   Hedman, Håkan ^b   Niclou, Simone P ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

alginate; cell encapsulation; EGFR; glioblastoma; glioma; Lrig1; tyrosine kinase receptors; xenograft models

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; RECOMBINANT LEUCINE RICH REPEATS AND IMMUNOGLOBULIN LIKE DOMAINS 1 PROTEIN; RECOMBINANT PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL ENCAPSULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENETIC VARIABILITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE;

ALGINATE; CELL ENCAPSULATION; EGFR; GLIOBLASTOMA; GLIOMA; LRIG1; TYROSINE KINASE RECEPTORS; XENOGRAFT MODELS;

ANIMALS; BRAIN NEOPLASMS; CELL LINE; GLIOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878611766     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not054     Document Type: Article

References (41)

1. Palazzo A, Iacovelli R, Cortesi E. Past, present and future of targeted therapyinsolid tumors. Current Cancer Drug Targets.2010;10:433-461.
2. Network CGAR. Comprehensive genomiccharacterizationdefineshuman glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.
3. Ekstrand AJ, Sugawa N, James CD, et al. Amplifiedand rearrangedepider-mal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc Natl Acad Sci USA. 1992;89:4309-4313.
4. Hatanpaa KJ, Burma S, Zhao D, et al. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 2010;12:675-684.
5. Gur G, Rubin C, Katz M, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004;23:3270-3281. (Pubitemid 39209151)
6. Laederich MB, Funes-Duran M, Yen L, et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem. 2004;279:47050-47056. (Pubitemid 39518360)
7. Guo D, Holmlund C, Henriksson R, et al. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics. 2004;84:157-165. (Pubitemid 38760139)
8. Holmlund C, Nilsson J, Guo D, et al. Characterization and tissue-specific expression of human LRIG2. Gene. 2004;332:35-43. (Pubitemid 38624248)
9. Nilsson J, Vallbo C, Guo D, et al. Cloning, characterization, and expression ofhumanLIG1.BiochemicalandBiophysicalResearchCommunications. 2001;284:1155-1161.
10. Jensen KB, Collins CA, Nascimento E, et al. Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell. 2009;4:427-439.
11. Powell AE, Wang Y, Li Y, et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell. 2012;149:146-158.
12. Wong VW, Stange DE, Page ME, et al. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol. 2012;14:401-408.
13. Suzuki Y, Miura H, Tanemura A, et al. Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett. 2002;521:67-71. (Pubitemid 34628460)
14. Hedman H, Nilsson J, Guo D, et al. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?. Acta Oncol. 2002;41:352-354.
15. Guo D, Nilsson J, Haapasalo H, et al. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol. 2006;111:238-246.
16. Holmlund C, Haapasalo H, Yi W, et al. CytoplasmicLRIG2 expressionisas-sociated with poor oligodendroglioma patient survival. Neuropathology. 2009;29:242-247.
17. Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling-double-edged swords in human cancer?. Eur J Cancer. 2007;43:676-682. (Pubitemid 46502902)
18. Thomasson M, Wang B, Hammarsten P, et al. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer. 2011;128: 2843-2852.
19. Krig SR, Frietze S, Simion C, et al. Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERalpha-positive breast cancer. Mol Cancer Res. 2011;9:1406-1417.
20. Yi W, Holmlund C, Nilsson J, et al. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res. 2011;317:504-512.
21. Goldoni S, Iozzo RA, Kay P, et al. A soluble ectodomain of LRIG1 inhibits cancercellgrowthbyattenuatingbasalandligand-dependentEGFRactiv-ity. Oncogene. 2007;26:368-381. (Pubitemid 46122827)
22. Li F, Ye ZQ, Guo DS, et al. Suppression of bladder cancer cell tumorigenic-ity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1. Oncol Rep. 2011;26:439-446.
23. Shattuck DL, Miller JK, Laederich M, et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol. 2007;27:1934-1946.
24. Ledda F, Bieraugel O, Fard SS, et al. Lrig1 is anendogenous inhibitor ofRet receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci. 2008;28:39-49.
25. Stutz MA, Shattuck DL, Laederich MB, et al. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRv III. Oncogene. 2008;27:5741-5752.
26. Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A. 2011;108:3749-3754.
27. Bjerkvig R, Tonnesen A, Laerum OD, et al. Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg. 1990;72:463-475. (Pubitemid 20072971)
28. Niclou SP, Danzeisen C, Eikesdal HP, et al. AnoveleGFP-expressing immu-nodeficient mouse model to study tumor-host interactions. Faseb J. 2008;22(9):3120-3128.
29. Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand. 1968;74:465-486.
30. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA. 1994;91:7727-7731. (Pubitemid 24238258)
31. Naldini L, Blomer U, Gallay P, et al. Invivo gene delivery and stable transduc-tion of nondividing cells bya lentiviral vector. Science. 1996;272:263-267. (Pubitemid 26119138)
32. Ahmed BY, Chakravarthy S, Eggers R, et al. Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors. BMC Neurosci. 2004;5:4.
33. Garcia P, Youssef I, Utvik JK, et al. Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J Neurosci. 2010;30:7516-7527.
34. Golebiewska A, Brons NH, Bjerkvig R, et al. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell. 2011;8:136-147.
35. Niclou SP, Bjerkvig R. Treatment of brain tumors with micro-encapsulated cell therapy, In: Hallé, J.P. d VP, Rosenberg, L.ed. The BioartificialPancreas and other Biohybrid Therapies. Canada: Research Signpost, 2009.
36. Visted T, Bjerkvig R, Enger PO. Cell encapsulation technology as a therapeutic strategy for CNS malignancies. Neuro Oncol. 2001;3:201-210. (Pubitemid 33674112)
37. Rajcevic U, Petersen K, Knol JC, et al. iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics. 2009;8:2595-2612.
38. Sakariassen PO, Prestegarden L, Wang J, et al. Angiogenesis-independent tumorgrowth mediatedbystem-likecancer cells. ProcNatlAcad Sci USA. 2006;103:16466-16471.
39. Wang J, Miletic H, Sakariassen PO, et al. A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer. 2009;9:465.
40. De Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma:asys-tematic review of clinical studies. Neuro-Oncology. 2010;12:304-316.
41. Read TA, Sorensen DR, Mahesparan R, et al. Localendostatintreatmentof gliomas administered by microencapsulated producer cells. Nat Biotechnol. 2001;19:29-34. (Pubitemid 32054367)